Inhibitor Therapeutics, Inc. (INTI)

Every figure this model derived for INTI, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2022-09-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
cash 515,758 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 586,806 AssetsCurrent 2026-06-30
current liabilities 174,894 LiabilitiesCurrent 2026-06-30
equity -2,559,270 StockholdersEquity 2026-06-30
interest expense 23,234 InterestExpense 2022-12-31
revenue 0 Revenues 2022-09-30
sbc 0 ShareBasedCompensation 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up INTI on one particular measure came for.

RatioValue
current ratio3.36
current ratio reported3.36

What to be careful about

What this model itself distrusts about INTI's figures. Written by the derivation as it ran, not added afterwards.